TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05308433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: The volunteer will have to imagine the smells evoked by different visual aids. This task will be carried out during 2 acquisition runs of about 10 minutes each. The volunteer should note (on a scale from 1 to 4) the pleasantness of the smell evoked.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality: control
Description: The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. In the center of the maritime scene, it will be visible the black outlines of a frame. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality: experimental
Description: The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. The visual support inserted in the center of the virtual scene will be the one defined as being the most facilitator of the olfactory imagination during the fMRI examination. The volunteer will be asked to concentrate on the smell evoked by this support. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
Study: NCT06343753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid free analgesia
Description: o Group OFA: Opioid free anesthesia Analgesia will be provided by syringe containing ketamine, Lidocaine and Dexmedetomidine in induction and maintenance according to lean body weight (LBW).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based Anesthesia
Description: o Group TBA: Traditional balanced anesthesia Analgesia will be provided by fentanyl in induction and maintenance according to Ideal Body Weight (IBW)
Study: NCT06579625

Intervention type: OTHER
Group type: OTHER
Intervention: Cancer education
Description: Participants in the experimental group will receive cancer education.
Study: NCT05582798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha 1-Proteinase Inhibitor 180mg/kg
Description: alpha1-proteinase inhibitor (human) intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha 1-Proteinase Inhibitor 120mg/kg
Description: alpha1-proteinase inhibitor (human) intravenous infusion
Study: NCT05311371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise group
Description: The exercise was applied in accordance with the Guideline on Breathing Exercise for Reducing Nausea and Vomiting prepared by the researcher in accordance with the literature. In addition, the researcher has a breath coaching certificate. The guideline include the application steps of breathing exercise. First, the researcher will demonstrate to the patients the practice of breathing exercise in accordance with the guideline. In the next step, patients they will be asked to do this application on themselves. The training is planned to take about 15-20 minutes for each patient. This guide will be given to patients after the training. They will be asked to do this breathing exercise correctly and effectively in accordance with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days. The researcher will follow up the patients for 14 days by visiting room them every day.
Study: NCT05582798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride 09.% intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride 09.% intravenous infusion
Study: NCT05131672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open reduction and internal fixation (ORIF)
Description: open reduction and internal fixation with pin or screw fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cast immobilization
Description: immobilization in a cast without reduction
Study: NCT05924321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Single infusion of Carbetocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion of matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and Moxifloxacin
Description: Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
Study: NCT06581679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel-releasing intrauterine system
Description: The levonorgestrel-releasing intrauterine system releasing 20 levonorgestrel daily.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: frozen embryo transfer
Description: Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.~The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: frozen embryo transfer
Description: Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.~The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur.
Study: NCT06581952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poem writing
Description: The poem themes will focus on accomplishment moments, joyful moments, and gratitude. Participants will be motivated to write at least one poem in each session. The instructor will lead the participants to improve the poem after the participants complete the first draft. The participants will be encouraged to perform in reading their completed poem, sharing their feelings and expressing the meaning of the poems during the session.~In the second session, participants will be invited to do a poem reading performance using one of their newly written poems.
Study: NCT06581315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib 100 mg twice daily (BID)
Study: NCT05452018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: In healthy volunteers, activity measurement of muscles of interest by intramuscular electromyography during predefined swallowing tasks
Study: NCT05311371

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No intervention
Study: NCT05791474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2231
Description: Provided by Aclaris Therapeutics, Inc.
Study: NCT05582070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: actigraphy
Description: Actigraphy examination will be performed during 2 periods of 7 days before and after nose nasal desobstruction surgery (septoplasty, septorhinoplasty or total ethmoidectomy). Respectively 2 months before surgery (inclusion) and 4 months after surgery.
Study: NCT00062530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCBaL/M9
Description: Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
Study: NCT06003556

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-1007 Positron Emission Tomography (PET) scan
Description: Additional staging PET scan prior to focal therapy to focal therapy.
Study: NCT04779255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procedure (Tumesent anesthesia)
Description: Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm (Paracetamol)
Description: Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
Study: NCT06155591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Nurse Case Manager (CNCM)
Description: Their action protocol has been designed and sequenced according to the circumstances in which the Complex and Pluripathological Chronic Patient finds themself:~* Pre-hospital discharge. The hospital Nurse Case Manager (HNCM) will contact the CNCM to inform of the imminent hospital discharge.~* Hospital discharge: A comprehensive nursing assessment of the CPCP based on Marjory Gordon's functional patterns will be carried out.~* Planned visits: An infographic will be provided to identify signs and symptoms of decompensation/exacerbation and a direct dial telephone number.~* Proactive telephone follow-up: The CNCM will make comfort calls every week for the first month, every 15 days until the 3-months visit and every month until the 6- and 12-months visits.~* Exacerbations/decompensations: An appointment will be arranged with their Primary Care physician.~* Hospital readmission: The CNCM will be kept informed of the process through the HNCM and CPCP's digital clinical history.
Study: NCT05089864

Intervention type: OTHER
Group type: OTHER
Intervention: Stent Placement Timing - Late
Description: Stent placement 12-14 weeks after STAR procedure
Study: NCT06537414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered
Study: NCT06134726

Intervention type: DIAGNOSTIC_TEST
Intervention: seropositivity of rheumatoid factor
Description: All participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies

Intervention type: DIAGNOSTIC_TEST
Intervention: seropositivity of rheumatoid factor
Description: All participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies
Study: NCT05077332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 80 mg tablet, QID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg (initial dose) then 200 mg capsule, BID for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, QID for 14 days; capsule, BID for 5 days
Study: NCT06371521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sportlegs
Description: Sportlegs contains lactate (from calcium lactate pentahydrate and magnesium lactate dihydrate), magnesium (from magnesium lactate dihydrate), calcium (from calcium lactate pentahydrate), and vitamin D (as cholecalciferol).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sportlegs
Description: Sportlegs contains lactate (from calcium lactate pentahydrate and magnesium lactate dihydrate), magnesium (from magnesium lactate dihydrate), calcium (from calcium lactate pentahydrate), and vitamin D (as cholecalciferol).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Empty Capsules to serve as a placebo control

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Empty Capsules to serve as a placebo control
Study: NCT06307054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CLL-1 CAR NK cells
Description: Eligible patients enrolled in the study after screening will receive lymphocyte collection(from the patient or a donor ) and receive single dose CLL-1 CAR NK cells infusion after a successful cell production. There are a total of four cell dose level:5×10\^6 CAR-NK cells/kg,1×10\^7CAR-NK cells/kg,2×10\^7CAR-NK cells/kg,4×10\^7CAR-NK cells/kg
Study: NCT04927806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Knight
Description: Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~* Staphyloccus epidermis~* Pseudomonas aeruginosa~* Klebsiella pneumoniae~* Acinetobacter calcoaceticus~* Escherichia coli
Study: NCT06485947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab beta
Description: Combination of immunotherapy with standard chemotherapy
Study: NCT06040437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be-Prox
Description: Be-Prox is an intervention developed to prevent, uncover and handle negative behavior in kindergartens.
Study: NCT06624475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully humanized monoclonal antibody that binds to the PD-1 receptor, blocking its interactions with PD-L1 and PD-L2, and thus additionally inhibiting PD1-driven immune suppression. Nivolumab 490 mg via IV administration 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdualag
Description: Opdualag (Opdualag) is supplied as a single dose vial containing 240 mg of Nivolumab and 80 mg. Relatlimab per 20 mL for intravenous administration ; 28 day cycle.
Study: NCT06624839

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human papillomavirus (HPV) vaccine, 9-valent
Description: 0.5 ml intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus (HPV) vaccine, 9-valent
Description: 0.5 ml intramuscular injection
Study: NCT06321263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Muscle Training and step aerobics training
Description: First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training and step aerobics training
Description: First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
Study: NCT06400745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPO Pro IOL
Description: Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPO Pro IOL
Description: Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPO IOL
Description: Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPO IOL
Description: Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
Study: NCT05839210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIFE-L Mediterranean Diet
Description: Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIFE-L Home-Based Exercise Program
Description: The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
Study: NCT05423444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: evidence-based psychotherapy for trauma in youth

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: treatment as usual
Study: NCT06724146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave and Pure Impact
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Pure Impact is an EMS module. This module is wirelessly connected to and controlled by the SofWave console. It functions independently from the existing ultrasound module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.
Study: NCT06727266

Intervention type: DIAGNOSTIC_TEST
Intervention: Shoulder ultrasound
Description: The ultrasound examination is performed according to the protocols of the European Society of Musculoskeletal Radiology (ESSR). The tendons of the muscles forming the rotator cuff, the enthesis regions, the tendon of the long head of the biceps muscle, the subacromial-subdeltoid bursa, the acromioclavicular and glenohumeral joints are examined.

Intervention type: DIAGNOSTIC_TEST
Intervention: Shoulder ultrasound
Description: The ultrasound examination is performed according to the protocols of the European Society of Musculoskeletal Radiology (ESSR). The tendons of the muscles forming the rotator cuff, the enthesis regions, the tendon of the long head of the biceps muscle, the subacromial-subdeltoid bursa, the acromioclavicular and glenohumeral joints are examined.
Study: NCT06713889

Intervention type: BIOLOGICAL
Intervention: Biocollection
Description: At each sampling time, 2 dry tubes of 4 ml, 1 EDTA tube of 4 ml, and 1 heparinised tube of 4 ml, i.e. a total of 16 ml per sampling time.~Group A patients will be sampled at inclusion, before, during and after the TAVI procedure, at 1 month follow-up and at 1 year follow-up, for a total of 120 ml. Patients in groups B and C will be sampled at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up, for a total of 80 ml.
Study: NCT06485947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab beta
Description: Combination of immunotherapy with standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy treatment called GPOH
Description: chemotherapy treatment called GPOH
Study: NCT06713889

Intervention type: BIOLOGICAL
Intervention: Biocollection
Description: At each sampling time, 2 dry tubes of 4 ml, 1 EDTA tube of 4 ml, and 1 heparinised tube of 4 ml, i.e. a total of 16 ml per sampling time.~Group A patients will be sampled at inclusion, before, during and after the TAVI procedure, at 1 month follow-up and at 1 year follow-up, for a total of 120 ml. Patients in groups B and C will be sampled at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up, for a total of 80 ml.

Intervention type: BIOLOGICAL
Intervention: Biocollection
Description: At each sampling time, 2 dry tubes of 4 ml, 1 EDTA tube of 4 ml, and 1 heparinised tube of 4 ml, i.e. a total of 16 ml per sampling time.~Group A patients will be sampled at inclusion, before, during and after the TAVI procedure, at 1 month follow-up and at 1 year follow-up, for a total of 120 ml. Patients in groups B and C will be sampled at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up, for a total of 80 ml.

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: EQ-5D-5L and HAD questionnaire at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: EQ-5D-5L and HAD questionnaire at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: EQ-5D-5L and HAD questionnaire at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up
Study: NCT06742853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: AZD0780 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: AZD0780 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: AZD0780 tablet will be administered orally.
Study: NCT06485947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy treatment called rapid COJEC
Description: chemotherapy treatment called rapid COJEC